Nov. 5 at 7:02 PM
$ALZN IMO, it's kind of surprising that this stock, for the most part, is flying under the radar given that so many have so much riding on the latest clinical trial. First there is Alzn and shareholders, a 4 year trading stock that is running on fumes. Then there is Harvard, that would like nothing better than to score a big win for their research department, in light of recent funding cuts and political unrest. Next, QMENTA, who is eager to showcase their new AI generated software analysis. Finally, Telsa Dynamics' quote.--This is a monumental achievement in the quest for more effective and safer lithium-based therapies. The advanced imaging technology enabled by this coil has the potential to revolutionize the treatment of neurological disorders, offering hope to the millions of people affected by these conditions. As the "Lithium in Brain" Phase II clinical trials commence, the world watches with bated breath, eagerly anticipating the groundbreaking discoveries that lie ahead.
